IP Library Granted Patent US 10,933,171
Granted Patent B2
US 10,933,171 · App. 16/461,552 · Granted Mar 2, 2021

Collagen sol for submucosal local injection

Inventors: Toshio Uraoka (Tokyo, JP); Naohisa Yahagi (Tokyo, JP); Shunji Yunoki (Tokyo, JP); Yoshimi Ohyabu (Tokyo, JP); Takefumi Narita (Tokyo, JP)
Assignees: Tokyo Metropolitan Industrial Technology Research Institute; National University Corporation Gunma University
A61L31/047A61B17/28A61B17/32A61K9/06A61K31/352A61K47/02A61K47/22A61K47/42A61L31/04A61L31/044A61L31/14A61L31/16A61L33/12A61B17/320016
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,933,171
App. No.
16/461,552
Granted
Mar 2, 2021
Kind
B2
Abstract

Object of the present invention is to provide a safe sol for submucosal local injection which gels and creates a mucosal elevation having a high retention rate of mucosal elevation height when locally injected into a digestive submucosa. Provided is a sol for submucosal local injection containing from 0.2 mass % to 1.2 mass % of a collagen, water, a buffer, and from 200 mM to 420 mM sodium chloride.

Claims (12)

1. A method of treating a submucosa, which comprises injecting a sol comprising from 0.2 mass % to 1.2 mass % of a collagen, water, a buffer, and from 220 mM to 310 mM sodium chloride into the submucosa, wherein denaturation temperature of the collagen is 37° C. or more and 50° C. or less.

2. The method according to claim 1 , wherein the sol further comprises from 40 mg/L to 1400 mg/L of genipin or a genipin derivative.

3. The method according to claim 1 , wherein the sol has a pH from 6.0 to 9.0 and the buffer contains a phosphate.

4. The method according to claim 1 , wherein the sol comprises from 40 mg/L to 1400 mg/L of genipin or a genipin derivative.

5. An endoscope system for endoscopic mucosal resection or endoscopic submucosal dissection, comprising a unit for locally injecting a sol comprising from 0.2 mass % to 1.2 mass % of a collagen, water, a buffer, and from 220 mM to 310 mM sodium chloride, wherein denaturation temperature of the collagen is 37° C. or more and 50° C. or less.

6. The method according to claim 3 , wherein the sol comprises from 40 mg/L to 1400 mg/L of genipin or a genipin derivative.

7. The method according to claim 1 , wherein the sol forms a gel when injected.

8. The method according to claim 1 , wherein the sol results in a mucosal elevation when locally injected into the submucosa.

9. The system according to claim 5 , wherein the sol further comprises from 40 mg/L to 1400 mg/L of genipin or a genipin derivative.

10. The system according to claim 5 , wherein the sol has a pH from 6.0 to 9.0 and the buffer contains a phosphate.

11. The system according to claim 5 , wherein the sol forms a gel when injected.

12. The system according to claim 5 , wherein the sol results in a mucosal elevation when locally injected into the submucosa.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2021
From: URAOKA, TOSHIO
To: NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY
Reel/Frame 055082/0599 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 25, 2019
From: YUNOKI, SHUNJI; OHYABU, YOSHIMI; NARITA, TAKEFUMI
To: TOKYO METROPOLITAN INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
Reel/Frame 051104/0274 →
SECURITY INTEREST Recorded Nov 25, 2019
From: TOKYO METROPOLITAN INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE; KEIO UNIVERSITY; INDEPENDENT ADMINISTRATIVE AGENCY, NATIONAL HOSPITAL ORGANIZATION
To: URAOKA, TOSHIO
Reel/Frame 051104/0438 →
Priority Claims (1)
JP JP2016-224258 · Nov 17, 2016 · national
Continuity (1)
Related Publication 20190290808A1 · Sep 26, 2019